Navigation Links
In the Case of Epilepsy, Generic Drugs and Random Product Substitution are Not Always "Good Medicine"
Date:5/27/2009

Nisola LLC launches campaign for stricter regulatory approval requirements and continuity of product supply.

New York, NY (PRWEB) May 27, 2009 -- A recent report released by Wolters Kluwer Health predicts that by the end of the year, nearly two-thirds of all drug prescriptions will be filled with generic drugs. This march to generics is fueled by several factors, which include the current economy, ever-increasing co-payment requirements for brand name drugs and pharmacies' desire to increase their profits by filling prescriptions with high margin generics versus lower margin brand name medicines.

This reliance on generics is generally considered a positive shift in healthcare as the vast majority of patients see significant cost savings without any noticeable change in their treatment. However, in the case of many neurological disorders, especially epilepsy, switching from a brand to a generic or between generics can be extremely dangerous.

The primary problem with random product substitution is that the Food and Drug Administration (FDA) does not require generic drugs to definitively demonstrate therapeutic equivalence to their brand name counterparts (i.e., the same clinical efficacy and safety profile). In fact, for approval, the FDA only requires that the generic be bioequivalent (i.e., within a certain range of a brand name drug's potency as measured by single-dose blood tests in healthy volunteers). Additionally, pharmacies, in their quest for profits, not only push patients to switch from brand name drugs to generics, but often switch from one generic manufacturer to another. Most alarmingly from an epilepsy patient's perspective, this means that one can receive a different generic brand every time they refill their prescriptions. This is understandably a nightmare for a patient trying to regulate their medications to avoid both seizures and/or side effects.

&qu
'/>"/>

Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. Mutant gene causes epilepsy, intellectual disability in women
2. Novel Techniques Offers New Freedom to Patients with Parkinson's Disease, Epilepsy, Dystonia, and Tremor
3. Guidelines: Pregnancy Safe with Epilepsy, but Valproate Should be Avoided
4. GPhAs 2007 Annual Policy Conference Features Top Generic Industry CEOs; FDA, Government Officials; Wall Street Analysts
5. Mylan Commences Tender Offers and Consent Solicitations for Its 5.750% Senior Notes Due 2010 and 6.375% Senior Notes Due 2015 in Connection With Its Proposed Acquisition of Mercks Generic Pharmaceutical Business
6. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
7. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
8. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Coreg(R)
9. Generic prostate drug helps find high-risk cancers early
10. Perrigo Confirms Filing for Generic Version of Mucinex(R) and Announcement of Lawsuit by Adams Respiratory
11. Mylan Vice Chairman and CEO Robert J. Coury to Ring NYSE Closing Bell(R) in Celebration of Merck Generics Acquisition
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... NJ (PRWEB) July 29, 2014 ... the world’s leading healthcare suppliers will utilize the ... 1WorldSync’s product information network to share product information ... and other trading partners across their global supply ... Auto ID at B. Braun: "B. Braun serves ...
(Date:7/29/2014)... July 29, 2014 Mach7 Technologies, ... announced today the release of an enhanced version ... , Mach7’s Physician & Patient Portal enables ... Patients gain access to a comprehensive view of ... seamlessly consolidates complete patient care records and intelligently ...
(Date:7/29/2014)... Collierville, TN (PRWEB) July 29, 2014 ... to the reimbursement model of all hospitals. Studies show ... tsunami.[1] One simple, easy, low cost tool that ... organizational performance by 20 to 25%. , Their secret? ... to one anther at the end of an operational ...
(Date:7/29/2014)... (PRWEB) July 29, 2014 TMG ... Outsourcing solutions for health plans in the Medicare ... Medicaid markets recently held its annual Client Forum ... Under the conference theme, “Partners in Excellence: Navigating ... executives and operations leaders from TMG Health’s Client ...
(Date:7/29/2014)... Kathleen Doheny HealthDay ... Healthy women at low risk of cardiovascular disease may be ... a short time without harming their hearts, according to a ... Initiative, found that hormone replacement therapy had harmful effects on ... they began the hormone treatments, and much further past menopause. ...
Breaking Medicine News(10 mins):Health News:B. Braun Selects 1WorldSync Unique Device Identification and Product Information Solution 2Health News:B. Braun Selects 1WorldSync Unique Device Identification and Product Information Solution 3Health News:Mach7 Technologies’ Physician & Patient Portal Consolidates Patient Care Records across the Enterprise and Simplifies Image Sharing and Communication 2Health News:Mach7 Technologies’ Physician & Patient Portal Consolidates Patient Care Records across the Enterprise and Simplifies Image Sharing and Communication 3Health News:One Brilliant Economic Survival Tool You Can Steal from the World's Best Hospitals 2Health News:One Brilliant Economic Survival Tool You Can Steal from the World's Best Hospitals 3Health News:TMG Health Client Forum Explores Strategies for Success in the Post-Reform Market 2Health News:TMG Health Client Forum Explores Strategies for Success in the Post-Reform Market 3Health News:Early Hormone Therapy May Be Safe for Women's Hearts 2Health News:Early Hormone Therapy May Be Safe for Women's Hearts 3
... This release is available in French . ... enable the region to build research capacity and conduct clinical ... HIV/AIDS and Malaria for the conduct of clinical trials) is ... region to conduct high-quality clinical trials. It will be supported ...
... zeros in on root causes of defects on the ... whose assembly manufacturing quality systems are used by companies ... as they occur, has been named a preferred supplier ... cementing its position in a key growth market for ...
... MUNICH, Feb. 25 Smith & Nephew,s,Orthopaedics ... which,BrainLAB will become the exclusive vendor for developing ... high performance,hip and knee implants. , ... will begin work integrating,the Smith & Nephew portfolio ...
... of Texas M. D. Anderson Cancer Center ... Knife (R) Perfexion(TM), an advanced radiosurgery ... lesions in the head in a single session, ... )"Leksell Gamma Knife Perfexion suits our clinical needs," ...
... Mass. and GAITHERSBURG, Md., Feb. 25 ... a systems biology company focused on identifying ... develop novel therapeutics, molecular diagnostics and patient-specific ... a partnership agreement with Gene Logic, an ...
... Aton Pharma, Inc., a,diversified specialty pharmaceutical company, ... to the TIMOPTIC(R) product line from Merck & ... receptor,blocking agent indicated for the treatment of elevated ... glaucoma. As many as 2.25,million Americans suffer from ...
Cached Medicine News:Health News:CANTAM first African Network of Excellence for clinical trials 2Health News:Sciemetric makes the grade with major medical device manufacturer 2Health News:Smith & Nephew Orthopaedics and BrainLAB Announce Exclusive Computer-Assisted Surgery Development Agreement 2Health News:Smith & Nephew Orthopaedics and BrainLAB Announce Exclusive Computer-Assisted Surgery Development Agreement 3Health News:Smith & Nephew Orthopaedics and BrainLAB Announce Exclusive Computer-Assisted Surgery Development Agreement 4Health News:M. D. Anderson Cancer Center Acquires Leksell Gamma Knife Perfexion for Targeted Brain Lesion Treatments 2Health News:M. D. Anderson Cancer Center Acquires Leksell Gamma Knife Perfexion for Targeted Brain Lesion Treatments 3Health News:Genstruct and Gene Logic Collaborate on Systems Toxicology 2Health News:Genstruct and Gene Logic Collaborate on Systems Toxicology 3Health News:Genstruct and Gene Logic Collaborate on Systems Toxicology 4Health News:Aton Pharma Acquires U.S. TIMOPTIC(R) 2Health News:Aton Pharma Acquires U.S. TIMOPTIC(R) 3
(Date:7/29/2014)... 29, 2014  Drug development for hepatitis C ... rates and the intense need for curative therapy ... is underway as the market moves away from ... easily-tolerated, interferon-free oral therapies. Logo ... mega blockbuster Sovaldi is the first of these ...
(Date:7/29/2014)... WHEAT RIDGE, Colo. , July 29, 2014 ... technology company focused on developing a proprietary electromagnetic ... announced it entered into an agreement under which ... -based Continuation Investments Limited (COT) in an all-stock ... the Company will initially trade on the Australian ...
(Date:7/29/2014)... , July 29, 2014 China Biologic Products, ... leading fully integrated plasma-based biopharmaceutical company in ... to release second quarter 2014 financial results on Tuesday, ... The Company,s management will hold a conference call ... which is 8:00 p.m., Beijing Time on August 6, ...
Breaking Medicine Technology:A Treatment Revolution is Underway: All-Oral Therapies Transform Global Hepatitis C Antiviral Market 2A Treatment Revolution is Underway: All-Oral Therapies Transform Global Hepatitis C Antiviral Market 3A Treatment Revolution is Underway: All-Oral Therapies Transform Global Hepatitis C Antiviral Market 4The BioFusionary Corporation, Inc. Announces Intent To Complete Reverse Takeover Of Australia-Based Continuation Investments Limited 2The BioFusionary Corporation, Inc. Announces Intent To Complete Reverse Takeover Of Australia-Based Continuation Investments Limited 3China Biologic to Report Second Quarter 2014 Financial Results 2China Biologic to Report Second Quarter 2014 Financial Results 3
... 2011 /PRNewswire-iReach/ -- URINOZINC® Plus with Beta-Sitosterol, ... is now available for purchase at select Walmart stores. ... is the only dietary supplement with a US Patent ... Over 2 million bottles have been sold. ...
... CardioMEMS, Inc ., an Atlanta-based medical device company that ... and communication technology for the human body, today announced ... , has been honored with a Ernst & Young ... category for the Alabama/Georgia/Tennessee region.  According to Ernst & ...
Cached Medicine Technology:Walmart Stores Now Offer URINOZINC® Plus With Beta-Sitosterol 2Dr. Jay Yadav, CardioMEMS Founder & CEO, Named Ernst & Young Entrepreneur of the Year® 2Dr. Jay Yadav, CardioMEMS Founder & CEO, Named Ernst & Young Entrepreneur of the Year® 3
... with powder-coated steel legs. Height ... in hundreds of sizes and ... light fixtures and ionizing equipment. ... custom building to meet special ...
Round, height-adjustable, steel laboratory stools with small footprint for small spaces • Choose options like different height-adjustment mechanism or paint finish. • your choice of color...
... BioSafe room is configured specifically for ... chemical analysis. Panels are precision-joined to ... to wipe down and disinfect. One-inch ... panel design creates strong, rigid surface ...
... The ideal modular cleanroom for ... applications that require cleanliness (to Class ... are precision-joined to create ultra-smooth surfaces ... and disinfect. One-inch radius corners simplify ...
Medicine Products: